Scholars continue to employ both terms, some simply opting to reproduce the German word. A translation like "superior humans" might better fit the concept of Nietzsche as he unfolds his narrative. Kaufmann and others preferred to translate Übermensch as "overman". Walter Kaufmann lambasted this translation in the 1950s for two reasons: first, the failure of the English prefix "super" to capture the nuance of the German über (though in Latin, its meaning of "above" or "beyond" is closer to the German) and second, for promoting misidentification of Nietzsche's concept with the comic-book character Superman. In 1909, Thomas Common translated it as "Superman", following the terminology of George Bernard Shaw's 1903 stage play Man and Superman. In 1896, Alexander Tille made the first English translation of Thus Spoke Zarathustra, rendering Übermensch as "Beyond-Man".
5 Re-embodiment of amoral aristocratic values. 
3 Death of God and the creation of new values. We couldn’t be more excited to have the opportunity to serve all these interests through our platforms and technology, becoming a trusted advisor to consumers and a powerful resource for expansion for professionals and businesses serving these audiences. There seems to be a significant shift in the consciousness of younger generations, which reflects in the preferences for plant-based and animal cruelty-free products, fascination with plant medicine such as ayahuasca and mushroom ceremonies, and practices such as yoga or breathwork or sound meditation. The positive press and rapidly shifting public attitude, combined with significant early-momentum toward decriminalization, are reasons for confidence in a future where we have dramatically greater access to some of earth’s greatest resources for our wellbeing.Īs it turns out, despite the decades of stigma towards psychedelics, and immense promotion of the consumption of alcohol in the media, Millenials and Gen-Z have-against the odds-shown a major trend for swapping alcohol and many other intoxicants for psychedelics and cannabis. The avalanche of support from the celebrity and entrepreneur community, from Paul McCartney, Kristen Bell, and Joe Rogan to Steve Jobs and Tim Ferris, for the continued funding and investigation of psychedelics as therapeutic-aids, has also created tremendous visibility in mainstream media. It is now clear through hard-science that psychedelics are effective at treating an array of mental health indications. Thankfully, today there exists countless incredible studies bringing data and science-backed evidence to the forefront of our awareness, to show the power and potential of these compounds. Repairing the immense damage done by erroneous studies and data meant to convince the public of the extreme danger of psychedelics has taken time, and no doubt we as a civilization are paying the huge opportunity cost today for where mental healthcare and our understanding of consciousness could have been, but isn’t. adults who took part in a survey conducted by The Harris Poll in December, 2021.Īccording to the results, 83% of Americans experiencing anxiety, depression or PTSD would pursue alternative treatments to prescription medication.Īmong those polled, 66% said they would be open to using ketamine, 62% were in favor of psilocybin, and 56% showed support for MDMA if prescribed by a physician and proven to be more effective than prescription medication with fewer side effects.Īfter nearly five decades of government-perpetuated stigma as a result of propaganda and misinformation used to tie psychedelics to the counterculture movement of the 60’s and 70’s, the veil has finally begun to be lifted. The future looks promising: Two-thirds of Americans with treatment-resistant anxiety, depression or PTSD believe that psychedelics should be made available for therapeutic means, according to U.S. 
The exit-environment is extremely hot, especially for those companies fit for public listings. There are more than 40 psychedelic compounds in Phase 1 or later clinical trials. Approximately $350M of capital was deployed in 2020. 
The volume of private investment into psychedelic therapeutics companies in 2021 was in excess of $550M.
0 kommentar(er)
